Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Xeligekimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Xeligekimab is an injectable antibody for plaque psoriasis and ankylosing spondylitis. It was developed and is made in China by Chongqing Genrix Biopharmaceutical, and is sold there as 金立希® (Jinlixi). It comes in a pre-filled syringe for injection under the skin.
China's National Medical Products Administration (NMPA) has approved it for adults with:
It is a prescription immunology medicine and should be used only under a dermatologist or rheumatologist.
IL-17A is an immune messenger that drives the thick, scaly patches of psoriasis and the inflammation of the spine and tendons in ankylosing spondylitis. Xeligekimab is a fully human IgG4 monoclonal antibody that binds IL-17A and stops it from attaching to its receptor (IL-17RA), so the inflammatory chain reaction is switched down.
Psoriasis: the phase 3 trial, published in the British Journal of Dermatology in 2024, included 420 adults with moderate-to-severe plaque psoriasis. After 12 weeks, 90.7% of people on xeligekimab had at least 75% clearer skin (PASI 75), against 8.6% on placebo. 74.4% reached PASI 90 and 30.2% had completely clear skin (PASI 100). Itching eased from about week 4, and the benefit was maintained to week 52.
Ankylosing spondylitis: in a phase 3 trial of 465 adults (BioDrugs, 2025), 74.0% of people on 200 mg and 65.8% on 100 mg reached the ASAS20 response at week 16, compared with 35.9% on placebo. The improvement was sustained to week 48.
Each pre-filled syringe holds 100 mg in 1 mL. The doses studied in the pivotal trials were:
Your specialist will confirm the approved dose and schedule from the current Chinese prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Infections and tuberculosis: because this medicine works on the immune system, infections such as colds and sore throats are common. In the ankylosing spondylitis trial, upper respiratory infection affected 17.5% of people on 200 mg (19.2% on placebo). In that trial, people with latent tuberculosis were given preventive TB treatment for at least 4 weeks first, and no TB reactivation was seen. Tell your doctor about any infection or past TB before you start.
Overall: in the ankylosing spondylitis trial, side effects in the first 16 weeks were about as frequent as with placebo (87.0% on 200 mg vs 83.3%), and serious side effects occurred in 1.9% vs 1.3%. In the psoriasis trial, no unexpected side effects were recorded.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another psoriasis medicine we can import, see our page on Bimzelx.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is stored and shipped as directed on the pack, using temperature-controlled shipping all the way to the hospital or patient. Psoriasis doses use two syringes at a time, so we plan quantities around the dosing schedule. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital or clinic on a valid specialist's prescription.
Skin and joint specialists in Delhi can request the syringes for a named patient, dispatched from our New Delhi base.
Orders are timed around the two-weekly starting phase so no dose is missed.
Dermatologists in Bangalore can send the prescription and past treatment details to start the import.
Patients with ankylosing spondylitis can have supplies delivered to their treating hospital.
We share a written quote and delivery timeline before anything is ordered.
Shipments to Kolkata and the eastern states are handled under controlled conditions throughout.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating doctor can share earlier treatment history so the import file is complete from the start.
Patients treated at hospitals in Vellore can have supplies sent directly to the hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate delivery to public and private hospitals across Uttar Pradesh.
Patients across Kerala can receive the syringes at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
